A
Akero Therapeutics
AKRO
26.370
USD
-0.39
(-1.46%)
مغلق
حجم التداول
12,584
الربح لكل سهم
0
العائد الربحي
0
P/E
-9
حجم السوق
2,145,410,299
أصول ذات صلة
الأخبار
المقالات
العنوان: Akero Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.